文献速递心脑血管急症

新型高敏肌钙蛋白I检测与五种加速诊断路径排除急性心肌梗死及急性冠脉综合征的诊断准确性

Diagnostic Accuracy of a New High-Sensitivity Troponin I Assay and Five Accelerated Diagnostic Pathways for Ruling Out Acute Myocardial Infarction and Acute Coronary Syndrome.
PubMed 文献 · Ann Emerg Med · 2017-12-13
一句话结论在低患病率急诊胸痛队列中,采用Beckman Access高敏肌钙蛋白I联合新温哥华胸痛规则或无客观检测规则,约三分之一患者2小时风险分层后可安全离院无需进一步检测。

该诊断准确性研究在澳大利亚一家急诊科纳入1811例胸痛患者,用Beckman Access高敏肌钙蛋白I检测就诊时和2小时血样,评估5种加速胸痛路径。96例(5.3%)发生30天急性心肌梗死,139例(7.7%)发生急性冠脉综合征。新温哥华胸痛规则和无客观检测规则对急性心肌梗死敏感性均为100%(95%CI 96.2%–100%),对急性冠脉综合征敏感性分别为98.6%(95%CI 94.9%–99.8%)和99.3%(95%CI 96.1%–100%)。m-ADAPT、EDACS和HEART路径对急性心肌梗死敏感性高(96.9%–97.9%),但对急性冠脉综合征敏感性≤95.0%,且将更多患者归为低危(64.3%、62.5%、49.8%)。

要点

  • 新温哥华胸痛规则和无客观检测规则对30天急性心肌梗死敏感性均为100%(95%CI 96.2%–100%),对急性冠脉综合征敏感性分别为98.6%和99.3%。
  • 新温哥华胸痛规则将28.2%、无客观检测规则将34.5%的患者归为低危,约三分之一患者2小时风险分层后可安全离院无需进一步检测。
  • m-ADAPT、EDACS和HEART路径对急性心肌梗死敏感性96.9%–97.9%,但对急性冠脉综合征敏感性≤95.0%。
  • m-ADAPT、EDACS和HEART路径分别将64.3%、62.5%、49.8%的患者归为低危,可使半数急诊患者快速转诊接受客观检测。
  • 该队列急性心肌梗死患病率5.3%、急性冠脉综合征患病率7.7%,结论适用于低患病率人群。

适用人群与场景

  • 澳大利亚一家急诊科就诊的胸痛患者,共1811例,同时采集就诊时和2小时血样检测高敏肌钙蛋白I。

诊断标准与关键阈值

  • 低危分类采用5种规则:m-ADAPT、EDACS路径、HEART路径、无客观检测规则、新温哥华胸痛规则。
  • 终点为30天急性心肌梗死和急性冠脉综合征。

研究设计与关键结果

  • 诊断准确性研究,纳入1811例急诊胸痛患者,使用Beckman Access高敏肌钙蛋白I检测就诊时和2小时血样,评估5种加速胸痛路径。
  • 96例(5.3%)发生30天急性心肌梗死,139例(7.7%)发生急性冠脉综合征。
  • 新温哥华胸痛规则对急性心肌梗死敏感性100%(95%CI 96.2%–100%),对急性冠脉综合征敏感性98.6%(95%CI 94.9%–99.8%)。
  • 无客观检测规则对急性心肌梗死敏感性100%(95%CI 96.2%–100%),对急性冠脉综合征敏感性99.3%(95%CI 96.1%–100%)。
  • m-ADAPT对急性心肌梗死敏感性96.9%(95%CI 91.1%–99.4%),EDACS和HEART对急性心肌梗死敏感性均为97.9%(95%CI 92.7%–99.7%)。
  • m-ADAPT、EDACS和HEART对急性冠脉综合征敏感性均≤95.0%。
  • 低危分类比例:m-ADAPT 64.3%、EDACS 62.5%、HEART 49.8%、新温哥华胸痛规则28.2%、无客观检测规则34.5%。

证据类型、等级与局限

  • 证据类型:诊断准确性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在低患病率急诊胸痛队列中,使用Beckman Access高敏肌钙蛋白I联合新温哥华胸痛规则或无客观检测规则,约三分之一患者2小时风险分层后可安全离院无需进一步检测。
  • 使用EDACS、m-ADAPT或HEART路径可使半数急诊患者快速转诊接受客观检测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: This diagnostic accuracy study describes the performance of 5 accelerated chest pain pathways, calculated with the new Beckman's Access high-sensitivity troponin I assay.

METHODS: High-sensitivity troponin I was measured with presentation and 2-hour blood samples in 1,811 patients who presented to an emergency department (ED) in Australia. Patients were classified as being at low risk according to 5 rules: modified accelerated diagnostic protocol to assess patients with chest pain symptoms using troponin as the only biomarker (m-ADAPT), the Emergency Department Assessment of Chest Pain Score (EDACS) pathway, the History, ECG, Age, Risk Factors, and Troponin (HEART) pathway, the No Objective Testing Rule, and the new Vancouver Chest Pain Rule. Endpoints were 30-day acute myocardial infarction and acute coronary syndrome. Measures of diagnostic accuracy for each rule were calculated.

RESULTS: Data included 96 patients (5.3%) with acute myocardial infarction and 139 (7.7%) with acute coronary syndrome. The new Vancouver Chest Pain Rule and No Objective Testing Rule had high sensitivity for acute myocardial infarction (100%; 95% confidence interval [CI] 96.2% to 100% for both) and acute coronary syndrome (98.6% [95% CI 94.9% to 99.8%] and 99.3% [95% CI 96.1% to 100%]). The m-ADAPT, EDACS, and HEART pathways also yielded high sensitivity for acute myocardial infarction (96.9% [95% CI 91.1% to 99.4%] for m-ADAPT and 97.9% [95% CI 92.7% to 99.7%] for EDACS and HEART), but lower sensitivity for acute coronary syndrome (≤95.0% for all). The m-ADAPT, EDACS, and HEART rules classified more patients as being at low risk (64.3%, 62.5%, and 49.8%, respectively) than the new Vancouver Chest Pain Rule and No Objective Testing Rule (28.2% and 34.5%, respectively).

CONCLUSION: In this cohort with a low prevalence of acute myocardial infarction and acute coronary syndrome, using the Beckman's Access high-sensitivity troponin I assay with the new Vancouver Chest Pain Rule or No Objective Testing Rule enabled approximately one third of patients to be safely discharged after 2-hour risk stratification with no further testing. The EDACS, m-ADAPT, or HEART pathway enabled half of ED patients to be rapidly referred for objective testing.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Greenslade JH, Carlton EW, Van Hise C, et al. Diagnostic Accuracy of a New High-Sensitivity Troponin I Assay and Five Accelerated Diagnostic Pathways for Ruling Out Acute Myocardial Infarction and Acute Coronary Syndrome. Ann Emerg Med. 2017. PMID: 29248334. doi:10.1016/j.annemergmed.2017.10.030

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。